Scarica l'app Stockscreener
568.91
6.87%
-41.95
Pre-mercato:
569.40
0.49
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals Inc (REGN) Q1 2025 Earnings Call Highlights: Strong Dupixent Sales ... - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Q1 2025 Earnings Call Highl - GuruFocus
Regeneron Reports Strong Q1 2025 Financial Results - TipRanks
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $652.00 Price Target at Robert W. Baird - MarketBeat
Regeneron (REGN) Earnings Call: Growth Amid Challenges - TipRanks
Voya Investment Management LLC Sells 33,446 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Stifel Financial Corp Has $27.13 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Earnings call transcript: Regeneron Q1 2025 earnings miss, stock drops 8% - Investing.com
Regeneron Q1 2025 slides: Dupixent drives growth amid EYLEA challenges - Investing.com
Regeneron crumples under the weight of missed Eylea expectations - FirstWord Pharma
Another CRL Prompts Questions About Regeneron’s Regulatory Operations - insights.citeline.com
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Regeneron Crashes 7% On Major Miss For Blockbuster Eye Drug - Investor's Business Daily
Why Regeneron (REGN) Stock Is Moving Today - GuruFocus
Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides - Benzinga
Regeneron's Eylea franchise suffers double whammy with sales decline and surprise FDA rejection - Fierce Pharma
Regeneron Pharmaceuticals Stock Sinks as Eylea Q1 Sales Trail Estimates - MSN
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down - Zacks Investment Research
Regeneron (NASDAQ: REGN) Stock Drops: REGN Shares Fall Sharply - paginasiete.bo
Regeneron (REGN) Navigates Q1 Challenges with Strategic Growth P - GuruFocus
Regeneron’s first quarter 2025 results miss expectations - The Pharma Letter
Regeneron (REGN) Price Target Reduced Amid EYLEA Challenges | RE - GuruFocus
Regeneron's first-quarter results miss on lower Eylea demand - Reuters
Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More - MSN
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $925 - marketscreener.com
Spotify, Regeneron lead Tuesday’s market cap stock movers - Investing.com
Regeneron Stock Plummets After Earnings Miss - Barron's
Regeneron (REGN) Faces Setback with Q1 Sales Miss - GuruFocus
Regeneron Faces Setback With Eylea And FDA Rejection - Finimize
Regeneron drops as Eylea drives Q1 miss - MSN
Regeneron stock drops as Eylea drives Q1 miss (REGN:NASDAQ) - Seeking Alpha
EC approves Regeneron’s Lynozyfic for advanced multiple myeloma - World Pharmaceutical Frontiers
Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Regeneron Pharma's first-quarter results miss on lower Eylea demand - marketscreener.com
Regeneron Pharma's First-Quarter Results Miss on Lower Eylea Demand - US News Money
Regeneron Shares Tumble as Eylea Declines Make for a ‘Messy Quarter’ To Come - BioSpace
Regeneron Pharmaceuticals Q1 2025 Earnings: GAAP EPS of $7.27 Mi - GuruFocus
Regeneron Reports First Quarter 2025 Financial and Operating Res - GuruFocus
Regeneron (REGN) Q1 Earnings and Revenue Miss Estimates - GuruFocus
Regeneron (REGN) Q1 Revenue Falls Short of Expectations | REGN S - GuruFocus
Regeneron (REGN) Advances Pipeline and Strengthens Shareholder V - GuruFocus
Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma - PMLiVE
Regeneron: Q1 Earnings Snapshot - CTPost
REGENERON PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Regeneron Pharmaceuticals Reports Q1 2025 Financial Results - TradingView
Pinebridge Investments L.P. Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals' Q1 Adjusted Earnings, Revenue Fall - marketscreener.com
Regeneron (NASDAQ:REGN) Misses Q1 Sales Targets - Yahoo Finance
The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron - Yahoo Finance
Regeneron Unveils Massive $7B Growth Plan as Dupixent Sales Surge 19%, EYLEA HD Gains Momentum - Stock Titan
Nebula Research & Development LLC Sells 1,957 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma - Yahoo Finance
Familial Lipoprotein Lipase Deficiency Market Trends, Size, - openPR.com
Price T Rowe Associates Inc. MD Purchases 810,144 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Highlights New Real-World And Clinical Data On EYLEA HD At ARVO 2025 - Nasdaq
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Strong-Buy at Canaccord Genuity Group - MarketBeat
Aspergillosis Market Expected to Rise by 2034, Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, - Barchart.com
European Commission approves new multiple myeloma treatment - Investing.com
Regeneron Pharmaceuticals (NasdaqGS:REGN) Gains Conditional EC Approval For Lynozyfic In Multiple Myeloma - Yahoo Finance
NewEdge Advisors LLC Sells 1,630 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts? - Yahoo Finance
Regeneron wins EC approval for Lynozyfic in MM - The Pharma Letter
Regeneron expands US manufacturing with $3B Fujifilm partnership - Manufacturing Dive
Regeneron scores EU nod for bispecific antibody Lynozyfic, setting up clash with J&J and Pfizer - Fierce Pharma
1.38%
2.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):